Abstract: The present disclosure provides a sunscreen formulation with superior sensorial features, comprising a combination of sunscreen agents, and an emulsifier at particular weight concentrations to achieve said characteristics.
Claims:1. A sunscreen formulation comprising:
a. a combination of phenylbenzimidazole sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, and ethylhexyl methoxycinnamate; and
b. hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60,
wherein said combination of phenylbenzimidazole sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, and ethylhexyl methoxycinnamate weight concentration in said formulation is in the range of 0.3-20%; and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60 weight concentration in said formulation is in the range of 6-8%,
2. The formulation as claimed in claim 1, said formulation further comprising:
a. at least one bodying agent;
b. at least one neutralizer;
c. at least one film former;
d. at least one chelant; and
e. water.
3. The formulation as claimed in claim 1, wherein phenylbenzimidazole sulfonic acid weight concentration in said formulation is in the range of 0.1-5%, disodium phenyl dibenzimidazole tetrasulfonate weight concentration in said formulation is in the range of 0.1-5%, and ethylhexyl methoxycinnamate weight concentration in said formulation is in the range of 0.1-10%.
4. The formulation as claimed in claim 3, wherein phenylbenzimidazole sulfonic acid weight concentration in said formulation is 2.5%, disodium phenyl dibenzimidazole tetrasulfonate weight concentration in said formulation is 2.2% and ethylhexyl methoxycinnamate weight concentration in said formulation is 9.75%.
5. The formulation as claimed in claim 1, wherein hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60 weight concentration in said formulation is 6.5%.
6. The formulation as claimed in claim 2, wherein
a. at least one bodying agent is selected from the group consisting of acrylates/C10-30 alkyl acrylate crosspolymer with electrolyte tolerance (Ultrez 20, Ultrez 21, or Ultrez 30), having weight concentration in said formulation in the range of 0.1-2%;
b. at least one neutralizer is selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, diethanolamine, triethanolamine, 2-dimethylamino-2-methyl-1-propanol (DAMP), and 2-aminomethyl-1propanol (aminomethyl propanol) (AMP), in quantity sufficient to achieve a pH of said formulation in the range of 6-8;
c. at least one film former is selected from the group consisting of acrylate/octylacrylamide copolymer, acrylates copolymer, acrylates/C12-22 alkyl methacrylate copolymer, butylated PVP, and VA/butyl maleate/isobornyl acrylate copolymer vinyl caprolactam/VP/dimethylaminoethyl methacrylate copolymer, having weight concentration in said formulation in the range of 0.5-1.5%;
d. at least one chelant is selected from the group consisting of dimercaptosuccinic acid (DMSA), dimercapto-propane sulfonate (DMPS), alpha lipoic acid (ALA), calcium disodium versante (CaNa2-EDTA), disodium EDTA, and dimercaprol (BAL), having weight concentration in the range of 0.05-0.1%; and
e. water up to 100%.
7. The formulation as claimed in claim 6, comprising:
a. disodium EDTA having weight concentration in said formulation of 0.05%;
b. acrylates copolymer having weight concentration in said formulation of 1%;
c. triethanolamine having weight concentration in said formulation of 2.45%;
d. acrylates/C10-30 alkyl acrylate crosspolymer having weight concentration in said formulation of 0.1%;
e. ethyl hexyl methoxycinnamate having weight concentration in said formulation of 9.75%;
f. disodium phenyl dibenzimidazole tetrasulfonate having weight concentration in said formulation of 2.2%;
g. phenylbenzimidazole sulfonic acid having weight concentration in said formulation of 2.5%;
h. hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60 having weight concentration in said formulation of 6.5%; and
i. water to make up to 100%.
8. A method of preparing a formulation as claimed in claim 7, said method comprising:
a. preparing a water phase by contacting water, disodium EDTA, acrylates copolymer, and acrylates/C10-30 alkyl acrylate crosspolymer at a temperature in the range of 25-300C and mixing at 500-650 rpm to obtain a mixture A;
b. contacting triethanolamine to said mixture A to obtain a water phase mixture B;
c. contacting disodium phenyl dibenzimidazole tetrasulfonate, and phenylbenzimidazole sulfonic acid with triethanolamine to obtain a pre-neutralized sunscreen solution C having pH in the range of 6-8;
d. contacting pre-neutralized sunscreen solution C with water phase mixture B to obtain a mixture D; and
e. contacting ethyl hexyl methoxycinnamate, and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60 with mixture D at a temperature in the range of 25-300C under continuous stirring at 450-500 rpm obtain said formulation.
9. A method of preparing a formulation as claimed in claim 2, said method comprising:
a. preparing a water phase by contacting water, at least one chelant, at least one film former, and at least one bodying agent at a temperature in the range of 25-30°C and mixing at 500-650 rpm to obtain a mixture A;
b. contacting at least one neutralizer to said mixture A to obtain a water phase mixture B;
c. contacting disodium phenyl dibenzimidazole tetrasulfonate, and phenylbenzimidazole sulfonic acid with at least one neutralizer to obtain a pre-neutralized sunscreen solution C having pH in the range of 6-8;
d. contacting pre-neutralized sunscreen solution C with water phase mixture B to obtain a mixture D; and
e. contacting ethyl hexyl methoxycinnamate, and hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer (and) isohexadecane (and) polysorbate 60 with mixture D at a temperature in the range of 25-30°C under continuous stirring at 450-500 rpm obtain said formulation.
, Description:As Attached
| # | Name | Date |
|---|---|---|
| 1 | Form 5 [26-02-2016(online)].pdf | 2016-02-26 |
| 2 | Form 3 [26-02-2016(online)].pdf | 2016-02-26 |
| 3 | Description(Complete) [26-02-2016(online)].pdf | 2016-02-26 |
| 4 | Other Patent Document [05-07-2016(online)].pdf | 2016-07-05 |
| 5 | Form 26 [05-07-2016(online)].pdf | 2016-07-05 |
| 6 | 201641006829-Power of Attorney-110716.pdf | 2016-07-29 |
| 7 | 201641006829-Form 1-110716.pdf | 2016-07-29 |
| 8 | 201641006829-Correspondence-F1-PA-110716.pdf | 2016-07-29 |
| 9 | 201641006829-FORM 18 [07-01-2020(online)].pdf | 2020-01-07 |
| 10 | 201641006829-FER.pdf | 2020-08-03 |
| 11 | 201641006829-FORM 4(ii) [02-02-2021(online)].pdf | 2021-02-02 |
| 12 | 201641006829-OTHERS [26-04-2021(online)].pdf | 2021-04-26 |
| 13 | 201641006829-FER_SER_REPLY [26-04-2021(online)].pdf | 2021-04-26 |
| 14 | 201641006829-CLAIMS [26-04-2021(online)].pdf | 2021-04-26 |
| 15 | 201641006829-Correspondence to notify the Controller [01-09-2021(online)].pdf | 2021-09-01 |
| 16 | 201641006829-Written submissions and relevant documents [21-09-2021(online)].pdf | 2021-09-21 |
| 17 | 201641006829-US(14)-HearingNotice-(HearingDate-07-09-2021).pdf | 2021-10-17 |
| 18 | 201641006829-PatentCertificate23-12-2023.pdf | 2023-12-23 |
| 19 | 201641006829-IntimationOfGrant23-12-2023.pdf | 2023-12-23 |
| 1 | ss201641006829E_03-08-2020.pdf |